OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500
Debt
Debt-to-Equity Ratio0.57
Current Ratio9.66
Quick Ratio9.50
Price-To-Earnings
Trailing P/E Ratio-4.73
Forward P/E Ratio-8.56
P/E GrowthN/A
Sales & Book Value
Annual Sales$47.50 million
Price / Sales21.57
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book6.59
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees82
Outstanding Shares38,010,000
Market Cap$1,022.38
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) issued its quarterly earnings results on Monday, May, 14th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.07. The company earned $0.87 million during the quarter. View OptiNose's Earnings History.
What price target have analysts set for OPTN?
4 brokers have issued twelve-month price objectives for OptiNose's shares. Their predictions range from $27.00 to $34.00. On average, they anticipate OptiNose's stock price to reach $30.75 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Ratings for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Supernus Pharmaceuticals (SUPN), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA) and Akcea Therapeutics (AKCA).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 57)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres& COO (Age 53)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
When did OptiNose IPO?
(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
Has OptiNose been receiving favorable news coverage?
Media headlines about OPTN stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. OptiNose earned a daily sentiment score of 0.10 on Accern's scale. They also gave press coverage about the company an impact score of 45.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $26.95.
How big of a company is OptiNose?
OptiNose has a market capitalization of $1.02 billion and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
